Results 291 to 300 of about 178,774 (332)
Transcatheter arterial chemoembolization with or without bevacizumab in hepatocellular carcinoma with portal vein invasion: a randomized trial. [PDF]
Cancer ImagingYang D, Wang H, Zhang Y, Yan B.
europepmc +1 more source
Bevacizumab in Pediatric Neuro-Oncology. [PDF]
Curr OncolSilverman J +6 more
europepmc +1 more source
Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report. [PDF]
Discov OncolLiu J, Zhao Z, Tian Y, Shao H.
europepmc +1 more source
Treatment Patterns and Survival Outcomes Among Patients With Hepatocellular Carcinoma.
JAMA Netw OpenLau-Min KS +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2005
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Lee M. Ellis, Peter Kirkpatrick
openaire +2 more sources
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Lee M. Ellis, Peter Kirkpatrick
openaire +2 more sources